Clinical Trial Update: Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating lazertinib in combination with pemetrexed and carboplatin for EGFR-sensitizing mutation-positive recurrent or metastatic non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lazertinib (lazertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Yonsei University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING